| Bioactivity | NC9 (Cbz-Lys(Acr)-PEG2-dansyl) is an irreversible transglutaminase (TG) inhibitor. NC9 inhibits osteoblast differentiation and mineralization. NC9 destabilizes microtubules. NC9 can be used for the research of osteoblast differentiation[1]. |
| Invitro | NC9 (50 μM；12 天) 降低 TG 活性降低至 51%，并减少 TG 介导的细胞层标记[1]。NC9 (50 μM；12 天) 抑制成骨细胞培养中的矿物沉积，减少细胞基质层中 Ca2+ 积累[1]。NC9 (50 μM；12 天) 阻断细胞外 collagen type I (COL I) 的分泌和沉积，减少纤维连接蛋白 (FN) 基质的形成，增加细胞骨架和基质中的 FN 水平[1]。NC9 (50 μM；12 天) 使微管不稳定，其中质膜 150kda Glu-微管蛋白水平降低，50kda 微管蛋白升高[1]。 |
| Name | NC9 |
| CAS | 1352090-52-8 |
| Formula | C35H47N5O8S |
| Molar Mass | 697.84 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Al-Jallad HF, et al. Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. PLoS One. 2011 Jan 20;6(1):e15893. |